Knight Therapeutics Inc. (TSE:GUD – Get Free Report) shares reached a new 52-week high on Thursday . The company traded as high as C$10.19 and last traded at C$10.16, with a volume of 7628 shares trading hands. The stock had previously closed at C$10.01.
Knight Therapeutics Stock Performance
The company has a quick ratio of 1.79, a current ratio of 2.28 and a debt-to-equity ratio of 4.29. The company has a 50-day moving average price of C$9.73 and a 200-day moving average price of C$8.59. The firm has a market capitalization of C$1.01 billion, a price-to-earnings ratio of 68.27, a P/E/G ratio of -1,013.50 and a beta of -0.29.
Knight Therapeutics (TSE:GUD – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported C($0.03) earnings per share (EPS) for the quarter. Knight Therapeutics had a return on equity of 1.91% and a net margin of 2.72%.The business had revenue of C$143.97 million during the quarter. As a group, equities research analysts forecast that Knight Therapeutics Inc. will post 0.1009486 earnings per share for the current year.
Knight Therapeutics Company Profile
Knight Therapeutics Inc, headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc’s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc, please visit the company’s web site at www.knighttx.com or www.sedarplus.ca.
Read More
- Five stocks we like better than Knight Therapeutics
- Can ServisFirst Keep Delivering?
- CoreWeave’s Vera Rubin Lead Comes Down to Speed, Power, and Scale
- Micron’s New 512GB Memory Module Deepens Its AI Infrastructure Advantage
- Banc of California Bets on Short-Term Pain
Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
